Stay updated on OpACIN-neo Optimal Combo Trial
Sign up to get notified when there's something new on the OpACIN-neo Optimal Combo Trial page.

Latest updates to the OpACIN-neo Optimal Combo Trial page
- Check4 days agoChange DetectedRevision label updated to v3.5.3, replacing the previous v3.5.2. This indicates a new page revision without altering the trial information.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision label updated to v3.5.2, replacing the previous v3.5.0.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check33 days agoChange Detected- Added the Nat Med 2026 PRADO-trial publication: Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis (Nat Med, 2026 Mar;32(3):952-963; Epub 2026 Jan 28). - Removed the earlier Nat Med ahead-of-print citation (Nat Med, 2026 Jan 28).SummaryDifference0.0%

- Check47 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No user-facing content changes were observed on the page.SummaryDifference0.0%

- Check54 days agoChange DetectedPage revision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check83 days agoChange DetectedAdministrative updates: a new system revision (v3.4.2) is added, and older notices (including a funding-lapse alert and revision v3.4.1) are removed. These changes do not alter study details.SummaryDifference0.4%

Stay in the know with updates to OpACIN-neo Optimal Combo Trial
Enter your email address, and we'll notify you when there's something new on the OpACIN-neo Optimal Combo Trial page.